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Abstract 
Background: The aim of this study was to construct a non-invasive model for acute right ventricular afterload 
increase by hypoxic pulmonary vasoconstriction. Intact animal models are vital to improving our understanding of 
the pathophysiology of acute right ventricular failure. Acute right ventricular failure is caused by increased afterload 
of the right ventricle by chronic or acute pulmonary hypertension combined with regionally or globally reduced 
right ventricular contractile capacity. Previous models are hampered by their invasiveness; this is unfortunate as the 
pulmonary circulation is a low-pressure system that needs to be studied in closed chest animals. Hypoxic pulmonary 
vasoconstriction is a mechanism that causes vasoconstriction in alveolar vessels in response to alveolar hypoxia. In 
this study we explored the use of hypoxic pulmonary vasoconstriction as a means to increase the pressure load on 
the right ventricle.
Results: Pulmonary hypertension was induced by lowering the FiO2 to levels below the physiological range in 
eight anesthetized and mechanically ventilated pigs. The pigs were monitored with blood pressure measurements 
and blood gases. The mean pulmonary artery pressures (mPAP) of the animals increased from 18.3 (4.2) to 28.4 (4.6) 
mmHg and the pulmonary vascular resistance (PVR) from 254 (76) dyns/cm5 to 504 (191) dyns/cm5, with a lowering 
of FiO2 from 0.30 to 0.15 (0.024). The animals’ individual baseline mPAPs varied substantially as did their response to 
hypoxia. The reduced FiO2 level yielded an overall lowering in oxygen offer, but the global oxygen consumption was 
unaltered.
Conclusions: We showed in this study that the mPAP and the PVR could be raised by approximately 100% in the 
study animals by lowering the FiO2 from 0.30 to 0.15 (0.024). We therefore present a novel method for minimally 
invasive (closed chest) right ventricular afterload manipulations intended for future studies of acute right ventricular 
failure. The method should in theory be reversible, although this was not studied in this work.
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Background
Heart failure with subsequent circulatory shock is usually 
ascribed to the left ventricle and the systemic circulation. 
However, in recent years much attention has been paid 
to acute right ventricular failure (ARVF) and its contri-
bution to circulatory shock, especially in intensive care 
medicine [1]. ARVF is most often caused by increased 
afterload of the right ventricle (RV) by chronic or acute 
pulmonary hypertension (PH) combined with region-
ally or globally reduced contractile capacity of the RV, 
although ARVF in the absence of PH is possible [2].
The pulmonary circulation is a low-pressure, low-resist-
ance system. An increase in pulmonary resistance instan-
taneously raises the RV end-systolic pressure and volume 
[2–4]. This prolongs the isovolumic contraction, short-
ens the ejection phase and results in a pumping mecha-
nism similar to that of the left ventricle. The result is both 
higher oxygen consumption and reduced oxygen supply, 
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as coronary perfusion is diminished by elevated intramyo-
cardial pressure. A normal RV can adapt to both chronic 
and, to a certain degree, acute afterload increases by 
hypertrophy. However, when the RV fails to compensate 
for the increased afterload, devastating progressive ARVF 
and total circulatory breakdown eventually develops.
There is certainly a need for more research on the 
mechanisms leading to ARVF as well as how to treat the 
condition [2]. With its complex nature, and because it is 
caused by relatively small pressure changes, it is impor-
tant to use good intact animal models to study the phe-
nomenon. Several previous large animal models have 
used open chest approaches [5–7]. We believe it is vital 
to keep the chest closed and leave the pericardium intact 
as these surgical manipulations alter the pressure-flow 
relations of the RV and the pulmonary circulation, and 
hence, disturb the ARVF model.
We therefore aimed to construct a new and feasible 
large animal model where the afterload of the RV could 
be changed—preferably reversibly—with minimal inva-
siveness and closed chest. In such a model the hemody-
namic effect of increased afterload on RV can be studied 
in detail, and it would be possible to include this method 
in different models of RV failure.
In the pulmonary vasculature, vasoconstriction occurs 
in response to hypoxia, termed hypoxic pulmonary vaso-
constriction (HPV). The mechanism acts in response to 
low alveolar pO2 and is a vital physiological function to 
direct blood to the ventilated alveoli, and thereby sub-
stantially reduce pulmonary shunting. With a decrease 
in alveolar pO2, HPV onsets within seconds [8], increases 
rapidly and gradually plateaus. The constriction is 
mainly localized in small resistance pulmonary arteries 
(PAs,  <200 µm) [9] and is reversible with restoration of 
alveolar normoxia. Global hypoxia will induce HPV in all 
lung segments, resulting in a rise in pulmonary vascular 
resistance (PVR), with estimates ranging from 50 to 300% 
[10]. HPV has been used as a means to increase both 
acute and chronic PVR in animal experiments [11], but 
there is no systematic description in the literature on how 
to use HPV to induce acute RV afterload increase in pigs.
In this study we explored the use of HPV as a means 
to increase the pressure load on the RV aiming to deter-
mine the fraction of inspired oxygen (FiO2) level yielding 
the desired effect without leading to serious dysoxia. We 
used the standard definition of PH as a mean pulmonary 
artery pressure (mPAP) of ≥25 mmHg at rest as the tar-
get level [12].
Methods
Animals, handling, anaesthesia, surgery and euthanasia
Eight outbred pigs (25% Duroc, 25% Yorkshire, 50% Nor-
wegian Landrace, 29–37  kg) were included in the study 
after approval from the Norwegian State Commission for 
Animal Experimentation. All the animals received human 
care in accordance with the European Convention for the 
Protection of Vertebrate Animals used for Experimental 
and Other Scientific Purposes.
The animals were premedicated with intramuscular 
diazepam 10 mg and azaperone 400 mg. Anaesthesia was 
induced through an intravenous access on the external 
ear with atropine 1.0 mg, fentanyl 8.0 μg/kg, thiopenthal 
sodium 4.0  mg/kg and ketamine hydrochloride 8.0  mg/
kg. Before intubation, 5  ml of 40  mg/ml lidocaine was 
applied to the larynx. The animals were ventilated in 
PRVC mode on a Servo-i respirator (Maquet, Getinge 
Group, Gothenburg, Sweden) with initial values of FiO2 
at 0.30, a tidal volume of 10  ml/kg, PEEP at 6  cmH2O 
and minute ventilation adjusted to maintain PaCO2 at 
4.5–5.5 kPa. Anaesthesia was maintained by an infusion 
of fentanyl 20 μg/(kg h) and midazolam 0.40 mg/(kg h). 
Based on clinical response this was supplemented with 
boluses of fentanyl 50  μg/ml as needed. Intravascular 
volume was maintained by a bolus of acetated Ringer’s 
solution 10 ml/kg, followed by a continuous infusion of 
10 ml/(kg h) throughout the experiment. 5000 IU heparin 
was administered i.v. to prevent clot formation.
Before cannulation we surgically prepared the left 
carotid artery and the right and left internal jugular 
vein. Two mono lumen catheters were inserted into 
the left carotid artery and the left internal jugular vein 
for invasive blood pressure monitoring, arterial blood 
gases and intravenous injections. A flow-directed pul-
monary artery catheter (PAC; Swan Ganz CCOmbo 7.5 
Fr, Edwards Lifescience, USA) was inserted in the right 
internal jugular vein and advanced into the pulmonary 
artery using classical pressure observations and fluoro-
scopic guidance and validation. The PAC provided cen-
tral venous pressure (CVP), pulmonary artery pressure 
(PAP) and was used to sample mixed venous blood gases. 
The PAC was connected to a Vigilance II monitor for 
continuous cardiac output (CO) measurements (Edwards 
Lifescience, USA). A bladder catheter was inserted by a 
mini-laparotomy.
At the end of the experiment, the animals were eutha-
nized with pentobarbital 100 mg/kg.
Study protocol and respirator manipulations
To induce HPV, the FiO2 had to be reduced to levels 
below the physiological range (the oxygen content in air 
at sea level is 20.9%, and equals an FiO2 of 0.21). In order 
to reduce the FiO2 to subnormal values, nitrogen was 
plugged into the air inlet of the respirator, and the ani-
mals were then ventilated with an oxygen and nitrogen 
mixture. The actual FiO2 was monitored via a side stream 
multi-gas analyser.
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After end of surgery the animals stabilized for 30 min 
before baseline measurements were recorded. PH was 
then induced by slowly reducing FiO2 on the respirator 
while monitoring the response in mPAP. When mPAP 
levels above 25  mmHg were reached, the animal rested 
for 30 new minutes before new measurements were 
recorded.
Data material, measurements and statistics
Vital variables [mean pulmonary artery pressure (mPAP), 
pulmonary wedged pressure (PWP), central venous pres-
sure (CVP), heart rate (HR), cardiac output (CO)] and 
arterial and mixed venous blood gases were measured 
at baseline and after establishing PH. Blood gases were 
processed by a Radiometer ABL 720 blood gas analyser 
(Radiometer, Brønshøj, Denmark).
Equations for calculating PVR, DO2 and VO2:
Only simple descriptive medical statistics and paired 
sample t tests were used in this study. All datas were 










+ (PaO2 × 0.0031)
Unit: ml O2/dl blood





SvO2 + (PvO2 × 0.0031)
Oxygen delivery (DO2) = CaO2 × CO × 10 Unit: ml O2/min
Oxygen consumption (VO2) = C(a− v)O2 × CO × 10
analysed in Excel (MS Excel for Mac 2011, Microsoft 
Corporation, USA) and R (version 3.1.1, The R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
The individual animals had substantially differ-
ent baseline mPAP values despite similar age, weight 
and handling, 18.3 (4.2) mmHg [mean (sd)] (range 
14–27 mmHg). The FiO2 level needed to increase mPAP 
above 25  mmHg also varied considerably, 0.15 (0.026) 
[mean (sd)], range 0.13–0.21. (In the one animal with a 
baseline mPAP above 25 mmHg, the FiO2 was lowered to 
0.15.) This yielded a highly significant overall increase in 
mPAP from 18.3 (4.2) to 28.4 (4.6) mmHg (p ≪ 0.0001) 
(Table  1). Since CO did not change, the change in PVR 
was also consistent in all animals: from 254(76) dyns/cm5 
to 504(191) dyns/cm5, yielding a p-value of 0.001 (Fig. 1). 
Blood gases taken at baseline and after reduction of 
FiO2 displayed a slight reduction in oxygen delivery 
(DO2) from 409 (92)  ml/min to 354 (52)  ml/min. This 
was not a statistically significant reduction with a p value 
of 0.14. Nor did it affect the oxygen consumption (VO2), 
which remained unchanged, from 195 (35) ml/min to 200 
(41) ml/min (Fig. 2). This was caused by increased oxygen 
extraction after induction of PH, with a highly signifi-
cant reduction in mixed venous oxygen saturation (SvO2) 
from 0.51 (0.076) to 0.36 (0.070), yielding a p - value 
of ≪0.0001 (Fig. 3). Additionally, there were no changes 
in lactate, pH or base excess from baseline to after FiO2 
reduction. For details, see Additional file 1.
Discussion
Reduction of FiO2 from 0.3 to 0.15 (0.024) is an efficient 
method for increasing the afterload of the RV, yielding 
an overall doubling of the PVR. The effect took place in 
all animals and should therefore be considered a reliable 
Table 1 Changes in mPAP, PWP and PVR from baseline to pulmonary hypertension
Both mPAP and PVR increase with reduction of FiO2 and globally induced hypoxic pulmonary vasoconstriction
FiO2 fraction of inspired oxygen, mPAP mean pulmonary arterial pressure, PWP pulmonary wedged pressure, CO cardiac output, PVR pulmonary vascular resistance

















1 0.30 22 11 3.5 251.4 0.15 34 11 3.9 471.8
2 0.30 17 7 3.2 250.0 0.21 31 7 4.0 480.0
3 0.30 17 7 2.4 333.3 0.13 25 7 3.0 480.0
4 0.30 14 7 2.2 254.5 0.13 25 5 3.9 410.3
5 0.30 17 7 4.5 177.8 0.14 26 8 4.5 320.0
6 0.30 15 8 3.4 164.7 0.14 25 8 2.9 469.0
7 0.30 27 6 4.3 390.7 0.15 36 6 2.5 960.0
8 0.30 17 9 3.0 213.3 0.15 25 9 2.9 441.4
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general physiological feature. As such, this method can 
be used in future studies of RV adaption to increased 
afterload; the combination with some method of regional 
or global RV contractility reduction should in theory 
induce ARVF (Additional file 1: Table S1).
There was considerable variation in individual animals’ 
baseline mPAPs and the FiO2 reduction needed for a suf-
ficient mPAP increase. One could therefore ask whether 
this kind of model should aim at increasing the mPAP (or 
PVR) above a clinical definition of PH, as was done in this 
study, or whether one should aim for a relative change in 
afterload in each respective animal, say, a 100% increase 
in mPAP (or PVR) from baseline. Either way, the FiO2 
reduction has to be adapted to the individual animal.
Some animals experienced a relatively large reduction 
of arterial oxygen saturation (SaO2) as a consequence 
of the FiO2 reduction, leading to decreased DO2 over-
all. This did not lead to a decreased VO2 because of an 
increased oxygen extraction. It should be noted, however, 
that this occurred in the stable situation 30  min after 
establishing the lower FiO2 value (Fig.  2). We noticed 
during the initial phase of FiO2 reduction a transient 
change in skin colour and a decline in plethysmographic 
measured SaO2. After some minutes with their new oxy-
gen supply, the animals regained their previous colour 
and SaO2 level. This immediate physiological instability 
after serious system perturbations followed by stabiliza-
tion after a few minutes is an interesting physiological 
feature that we have also experienced in other animal 
models.
Another word of caution is that in some of the pilot 
animals prior to this study, we lowered the FiO2 too rap-
idly to levels that were too low, yielding an extremely low 
SvO2. This is a very strong stimulus to the sympathetic 
nervous system, leading to tachycardia and a high CO 
to compensate for the hypoxia. The pulmonary circula-
tion is constructed to be able to receive large volumes of 
blood without increasing the pulmonary arterial pres-
sure. This is mainly caused by an increase of the total 
cross-sectional area of the pulmonary vasculature, result-
ing from passive distension and recruitment of collapsed 
vessels [13]. In this situation the animals ended up with 
an increased mPAP from baseline, but with the same or 
even a reduced PVR. It is therefore important to be very 
careful when using our method, because it approaches 
the limit of the animal’s ability to compensate.
In theory, this method of increasing mPAP and PVR 
by reducing FiO2 should be fully reversible. Unfortu-
nately, we did not study whether the mPAP returned to 
its baseline value after re-establishing normal FiO2, or 
the time frame needed for this to occur. In the literature, 
HPV is described as biphasic with one rapid and one late 
phase. The time aspect is inconclusively described with 
variations in onset and duration for both phases [10, 
13–15]. The long phase is said to last from 45 min to sev-
eral hours, but there are no conclusive descriptions of 







Fig. 1 Changes in PVR from baseline to pulmonary hypertension. 
The overall increase in PVR from baseline to pulmonary hypertension 
is approximately 100%, with a p-value of 0.001. PVR BL pulmonary 
vascular resistance at baseline, PVR PH pulmonary vascular resistance 
at pulmonary hypertension







Fig. 2 Changes in oxygen delivery and consumption from baseline 
to pulmonary hypertension. Neither DO2 nor VO2 changed with the 
reduction of FiO2 indicating minor disturbance to the model. DO2 BL 
oxygen delivery at baseline, VO2 BL oxygen consumption at baseline, 
DO2 PH oxygen delivery at pulmonary hypertension, VO2 PH oxygen 
consumption at pulmonary hypertension





Fig. 3 SO2 and SvO2 before and after decreased FiO2. There was 
some reduction with a large spread in SO2, and a large and significant 
change in SvO2 from baseline to pulmonary hypertension
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how long the hypoxia must be maintained for this phase 
to kick in, nor how fast the vascular tone is returned 
to normal with restoration of normoxia. This empha-
sizes the need for further investigation of the method’s 
reversibility.
This study was not designed to investigate RV changes 
as a consequence of increased afterload. In accord-
ance with the theory as described in the background, 
increased afterload itself should not be enough to cause 
failure in a healthy RV. This was also our impression 
during the study, as CVP remained unchanged and CO 
didn’t show any systematically decrease. However, a full 
assessment of RV’s adaption to changing loading condi-
tions requires assessment with conductance catheters or 
similar in order to extract pressure–volume loops [6, 11].
Resistance as defined in practical clinical medicine and 
in this manuscript as a measure of afterload is an applica-
tion of Ohm’s law where resistance = Δ pressure/flow. In 
reality, this is only valid for a system of linear flow. In the 
pulmonary (and systemic) circulation, flow is oscillatory, 
in which impedance is a better calculation of the overall 
afterload. The continuous flow and pressure signals are 
assessed by Fourier analyzes and then the pressure/flow 
relations are compared for the respective harmonics [16]. 
Thus, in order to examine impedance, high-resolution 
continuous pressure and flow signals are mandatory, 
which we did not have in this study.
Conclusion
We showed in this study that the mPAP and the PVR 
could be raised by approximately 100% in the study ani-
mals by lowering the FiO2 from 0.30 to 0.15 (0.024). The 
responses were individual, as were the baseline mPAPs. 
This FiO2 reduction led to reduced SaO2 and hence DO2 
in some animals, but the VO2 was not reduced after a 
stabilization period. We note that in the initial phase, the 
animals seemed to be unstable, with clinical signs of dys-
oxia, but they regained normal oxygenation after some 
minutes. Furthermore, this method should be used with 
some caution, as reducing FiO2 too rapidly might lead 
to sympathetic nervous activation with tachycardia and 
high CO, resulting in a secondary normalization of PVR 
despite high mPAP. The method should in principle be 
reversible, although we did not study this in this work. 
We therefore present a novel method for minimal-inva-
sive (closed chest) RV afterload manipulations intended 
for future studies of ARVF.
Additional file
Additional file 1: Table S1. Arterial and mixed venous blood gases at 
baseline and pulmonary hypertension.
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